Compare Sana Biotechnology Inc (SANA) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Invesco S&P 500 Momentum ETF — how do they compare? Sana Biotechnology Inc trades at $3.83 (market cap $1.13B), while Invesco S&P 500 Momentum ETF trades at $151.67. The key difference: Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | SPMO | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $5.92 | $161.66 |
52-Week Low | $2.68 | $107.84 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
SPMO, the Invesco S&P 500 Momentum ETF, trades at $151.88, up 2.14% today, reflecting strong momentum-driven performance. Technical indicators show a bullish trend with moving averages supporting upside, though RSI levels hint at potential overbought conditions. Recent news highlights its outperformance versus the S&P 500, with a 26% return year-to-date, driven by concentrated tech exposure and AI-fueled growth, despite higher volatility risks.
The outlook remains positive given persistent momentum factor strength and institutional inflows, but risks include sector rotation and elevated valuations. Investors should weigh the ETF's cost efficiency (0.13% expense ratio) against concentration in technology stocks, which could amplify losses during market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
